Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Fluconazole
Bayer Limited
J02AC; J02AC01
Fluconazole
150 milligram(s)
Capsule, hard
Product subject to prescription which may be renewed (B)
Triazole derivatives; fluconazole
Not marketed
2005-04-15
AZURE - FEXOFENADINE TABLETS - 120 MG - 3X10’S - CARTON - CUTTERGUIDE DIMENSION: 86 X 70 X 24 MM LAYOUT NO.: 20120948A-22B 86 MM 70 MM 24 MM SPACE FOR PHARMACODE SPACE FOR PHARMACODE 86 MM 70 MM 24 MM fexofenadine hydrochloride 120 mg film coated tablets Braille Content MA HOLDER: Azure Pharmaceuticals Ltd, 12 Hamilton Drive, The Rock Road Blackrock, Co. Louth, A91 T997, Ireland KEEP OUT OF THE SIGHT AND REACH OF CHILDREN PC: SN: EXP: BN: Fexofenadine Hydrochloride 120 MG Film-coated Tablets fexofenadine hydrochloride 30 film-coated tablets PA22871/004/002 30 film-coated tablets 30 film-coated tablets 30 film-coated tablets Fexofenadine Hydrochloride 120 MG Film-coated Tablets fexofenadine hydrochloride Fexofenadine Hydrochloride 120 MG Film-coated Tablets fexofenadine hydrochloride Fexofenadine Hydrochloride 120 MG Film-coated Tablets fexofenadine hydrochloride ORAL USE 24-HOUR RELIEF OF: • Sneezing • Itchy, runny or blocked nose • Itchy, red and watery eyes Each tablet contains 120 mg of fexofenadine hydrochloride. Also contains lactose. WHAT FEXOFENADINE HYDROCHLORIDE 120 MG FILM-COATED TABLETS IS USED FOR Relieves the symptoms associated with hay fever. Starts to work in one hour and lasts for 24 hours. Read the package leaflet before use. HOW TO TAKE Oral use. FOR ADULTS AND CHILDREN AGED 12 YEARS AND OVER The recommended dose is one tablet (120 mg) to be taken daily before a meal. CHILDREN UNDER 12 YEARS OF AGE: Not recommended. DO NOT TAKE IF You are allergic to fexofenadine or any of the other ingredients in this medicine. WARNINGS Talk to your doctor or pharmacist before taking this medicine if: - you have problems with your liver - you have problems with your kidneys - you have or ever had heart disease - you are elderly - you are pregnant or breast-feeding. Do not exceed the stated dose. If symptoms persist consult your doctor. 30 film-coated tablets AZURE JOB NO.: 02 VERSION NO.: OFF-PACK PHARMACODE NUMBER: XXX XXXXXXXXX AZ22025C Product Name Fexofenadine HCI 120 mg FC Tabs 30 Market Ireland C Read the complete document
Health Products Regulatory Authority 19 March 2024 CRN00F4QN Page 1 of 17 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT CanOral 150mg Capsule 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains Fluconazole 150 mg. Excipients with known effect Each hard capsule contains 141.0mg of Lactose Monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard Opaque light blue capsule (size 1) printed “CAN150”. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS CanOral 150mg Capsule is indicated in the following fungal infections in adults (see section 5.1): Acute vaginal candidiasis when local therapy is not appropriate. _Candidal balanitis _when local therapy is not appropriate_. _ Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Consideration should be given to official guidance on the appropriate use of antifungals. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS Single dose 150mg Special populations _Elderly _ Where there is no evidence of renal impairment, normal dose recommendations should be adopted. _Renal Impairment_ Fluconazole is predominantly excreted in the urine as unchanged active substance. No adjustments in single dose therapy are necessary. _Hepatic Impairment_ Limited data are available in patients with hepatic impairment, therefore fluconazole should be administered with caution to patients with liver dysfunction (see sections 4.4 and 4.8). Paediatric Population Health Products Regulatory Authority 19 March 2024 CRN00F4QN Page 2 of 17 Safety and efficacy for genital candidiasis indication in paediatric population has not been established. Current available data for other paediatric indications are described in section 4.8. If treatment is imperative in adolescents (from 12 to 17 years old), the posology should be the same as adults posology. Method of administration Read the complete document